The Coronavirus Disease 2019 (COVID-19) Outbreak in China—Summary of a China CDC Report (2024)

Table of Contents
Journals Podcasts Citation References

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy|Continue

JAMA

    Sign In

    Individual Sign In

    Sign inCreate an Account

    Access through your institution

    Sign In

    Purchase Options:

    Subscribe to the JAMA journal

    Select Your Interests

    Customize your JAMA Network experience by selecting one or more topics from the list below.

    • Academic Medicine
    • Acid Base, Electrolytes, Fluids
    • Allergy and Clinical Immunology
    • American Indian or Alaska Natives
    • Anesthesiology
    • Anticoagulation
    • Art and Images in Psychiatry
    • Artificial Intelligence
    • Assisted Reproduction
    • Bleeding and Transfusion
    • Cardiology
    • Caring for the Critically Ill Patient
    • Challenges in Clinical Electrocardiography
    • Climate and Health
    • Climate Change
    • Clinical Challenge
    • Clinical Decision Support
    • Clinical Implications of Basic Neuroscience
    • Clinical Pharmacy and Pharmacology
    • Complementary and Alternative Medicine
    • Consensus Statements
    • Coronavirus (COVID-19)
    • Critical Care Medicine
    • Cultural Competency
    • Dental Medicine
    • Dermatology
    • Diabetes and Endocrinology
    • Diagnostic Test Interpretation
    • Drug Development
    • Electronic Health Records
    • Emergency Medicine
    • End of Life, Hospice, Palliative Care
    • Environmental Health
    • Equity, Diversity, and Inclusion
    • Ethics
    • Facial Plastic Surgery
    • Gastroenterology and Hepatology
    • Genetics and Genomics
    • Genomics and Precision Health
    • Geriatrics
    • Global Health
    • Guide to Statistics and Methods
    • Guidelines
    • Hair Disorders
    • Health Care Delivery Models
    • Health Care Economics, Insurance, Payment
    • Health Care Quality
    • Health Care Reform
    • Health Care Safety
    • Health Care Workforce
    • Health Disparities
    • Health Inequities
    • Health Policy
    • Health Systems Science
    • Hematology
    • History of Medicine
    • Humanities
    • Hypertension
    • Images in Neurology
    • Implementation Science
    • Infectious Diseases
    • Innovations in Health Care Delivery
    • JAMA Infographic
    • Law and Medicine
    • Leading Change
    • Less is More
    • LGBTQIA Medicine
    • Lifestyle Behaviors
    • Medical Coding
    • Medical Devices and Equipment
    • Medical Education
    • Medical Education and Training
    • Medical Journals and Publishing
    • Melanoma
    • Mobile Health and Telemedicine
    • Narrative Medicine
    • Nephrology
    • Neurology
    • Neuroscience and Psychiatry
    • Notable Notes
    • Nursing
    • Nutrition
    • Nutrition, Obesity, Exercise
    • Obesity
    • Obstetrics and Gynecology
    • Occupational Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otolaryngology
    • Pain Medicine
    • Palliative Care
    • Pathology and Laboratory Medicine
    • Patient Care
    • Patient Information
    • Pediatrics
    • Performance Improvement
    • Performance Measures
    • Perioperative Care and Consultation
    • Pharmacoeconomics
    • Pharmacoepidemiology
    • Pharmacogenetics
    • Pharmacy and Clinical Pharmacology
    • Physical Medicine and Rehabilitation
    • Physical Therapy
    • Physician Leadership
    • Poetry
    • Population Health
    • Primary Care
    • Professional Well-being
    • Professionalism
    • Psychiatry and Behavioral Health
    • Public Health
    • Pulmonary Medicine
    • Radiology
    • Regulatory Agencies
    • Reproductive Health
    • Research, Methods, Statistics
    • Resuscitation
    • Rheumatology
    • Risk Management
    • Scientific Discovery and the Future of Medicine
    • Shared Decision Making and Communication
    • Sleep Medicine
    • Sports Medicine
    • Stem Cell Transplantation
    • Substance Use and Addiction Medicine
    • Surgery
    • Surgical Innovation
    • Surgical Pearls
    • Teachable Moment
    • Technology and Finance
    • The Art of JAMA
    • The Arts and Medicine
    • The Rational Clinical Examination
    • Tobacco and e-Cigarettes
    • Toxicology
    • Translational Medicine
    • Trauma and Injury
    • Treatment Adherence
    • Ultrasonography
    • Urology
    • Users' Guide to the Medical Literature
    • Vaccination
    • Venous Thromboembolism
    • Veterans Health
    • Violence
    • Women's Health
    • Workflow and Process
    • Wound Care, Infection, Healing

    Save Preferences

    Privacy Policy | Terms of Use

    This Issue

    Views 2,274,253

    Comments 10

    Viewpoint

    February 24, 2020

    ZunyouWu,MD, PhD1; Jennifer M.McGoogan,PhD1

    Author Affiliations Article Information

    • 1Chinese Center for Disease Control and Prevention, Beijing, China

    JAMA. 2020;323(13):1239-1242. doi:10.1001/jama.2020.2648

    中文 (chinese)

    COVID-19 Resource Center

    visual abstract icon Visual Abstract editorial comment icon Editorial Comment related articles icon Related Articles author interview icon Interviews multimedia icon Multimedia audio icon Listen to this article
    • Viewpoint Coronavirus Infections—More Than Just the Common Cold

      Catharine I.Paules,MD; Hilary D.Marston,MD, MPH; Anthony S.Fauci,MD

      JAMA

    • Viewpoint The 2019 Novel Coronavirus and Challenges for Global Health Governance

      Alexandra L.Phelan,SJD, LLM; RebeccaKatz,PhD, MPH; Lawrence O.Gostin,JD

      JAMA

    • Original Investigation Clinical Characteristics of Patients With 2019 Novel Coronavirus (2019-nCoV)–Infected Pneumonia in Wuhan, China

      DaweiWang,MD; BoHu,MD; ChangHu,MD; FangfangZhu,MD; XingLiu,MD; JingZhang,MD; BinbinWang,MD; HuiXiang,MD; ZhenshunCheng,MD; YongXiong,MD; YanZhao,MD; YirongLi,MD; XinghuanWang,MD; ZhiyongPeng,MD

      JAMA

    • Research Letter Clinical Characteristics of Patients With Novel Coronavirus (2019-nCoV) Infection Hospitalized in Beijing, China

      DeChang,MD, PhD; MingguiLin,MD; LaiWei,MD; LixinXie,MD; GuangfaZhu,MD; Charles S.Dela Cruz,MD, PhD; LokeshSharma,PhD

      JAMA

    • Viewpoint 2019 Novel Coronavirus—Important Information for Clinicians

      Carlosdel Rio,MD; Preeti N.Malani,MD, MSJ

      JAMA

    • Viewpoint Preparation for Possible Sustained Transmission of 2019 Novel Coronavirus

      David L.Swerdlow,MD; LynFinelli,DrPH, MS

      JAMA

    • Viewpoint US Emergency Legal Responses to Novel Coronavirus—Balancing Public Health and Civil Liberties

      Lawrence O.Gostin,JD; James G.HodgeJr,JD, LLM

      JAMA

    • Research Letter Novel Coronavirus Infection in Hospitalized Infants Under 1 Year of Age in China

      MinWei,MD; JingpingYuan,MD, PhD; YuLiu,PhD; TaoFu,PhD; XueYu,MS; Zhi-JiangZhang,MD, PhD

      JAMA

    • Viewpoint Preparing for the Most Critically Ill Patients With COVID-19: The Potential Role of ECMO

      GraemeMacLaren,MSc; DaleFisher,MBBS; DanielBrodie,MD

      JAMA

    • Viewpoint COVID-19 in Singapore—Experience and Critical Issues That Require Attention and Action

      John E. L.Wong,MBBS; Yee SinLeo,MBBS, MPH; Chorh ChuanTan,MBBS, PhD

      JAMA

    • Viewpoint COVID-19—New Insights on a Rapidly Changing Epidemic

      Carlosdel Rio,MD; Preeti N.Malani,MD, MSJ

      JAMA

    • Viewpoint Response to COVID-19 in Taiwan: Big Data Analytics, New Technology, and Proactive Testing

      C. JasonWang,MD, PhD; Chun Y.Ng,MBA, MPH; Robert H.Brook,MD, ScD

      JAMA

    • Viewpoint Priorities for the US Health Community Responding to COVID-19

      Amesh A.Adalja,MD; EricToner,MD; Thomas V.Inglesby,MD

      JAMA

    • Original Investigation Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore

      Barnaby EdwardYoung,MB, BChir; Sean Wei XiangOng,MBBS; ShirinKalimuddin,MPH; Jenny G.Low,MPH; Seow YenTan,MBBS; JiashenLoh,MBBS; Oon-TekNg,MPH; KalisvarMarimuthu,MBBS; Li WeiAng,Msc; Tze MinnMak,PhD; Sok KiangLau,PhD; Danielle E.Anderson,PhD; Kian SingChan,MBBS; Thean YenTan,MBBCh; Tong YongNg,MBBS; LinCui,PhD; ZubaidahSaid,MSc; LalithaKurupatham,MPH; Mark I-ChengChen,PhD; MonicaChan,BMBS; ShawnVasoo,MBBS; Lin-FaWang,PhD; Boon HuanTan,PhD; Raymond Tzer PinLin,MBBS; Vernon Jian MingLee,PhD; Yee-SinLeo,MPH; David ChienLye,MBBS; for the Singapore 2019 Novel Coronavirus Outbreak Research Team

      JAMA

    • Research Letter RT-PCR Test Results in Patients Recovered From COVID-19

      LanLan,MD; DanXu,MD; GuangmingYe,MD; ChenXia,MS; ShaokangWang,MS; YirongLi,MD, PhD; HaiboXu,MD, PhD

      JAMA

    • Viewpoint Diagnostic Testing for the Novel Coronavirus

      Joshua M.Sharfstein,MD; Scott J.Becker,MS; Michelle M.Mello,JD, PhD

      JAMA

    • Viewpoint Supporting the Health Care Workforce During the COVID-19 Global Epidemic

      James G.Adams,MD; Ron M.Walls,MD

      JAMA

    • Viewpoint From Containment to Mitigation of COVID-19 in the US

      Stephen M.Parodi,MD; Vincent X.Liu,MD, MSc

      JAMA

    • JAMA Insights Care for Critically Ill Patients With COVID-19

      SrinivasMurthy,MD, CM, MHSc; Charles D.Gomersall,MBBS; Robert A.Fowler,MD, CM, MSc

      JAMA

    • Viewpoint Critical Care and the COVID-19 Outbreak in Italy: Early Experience and Forecast

      GiacomoGrasselli,MD; AntonioPesenti,MD; MaurizioCecconi,MD

      JAMA

    • Viewpoint Managing COVID-19 in Low- and Middle-Income Countries

      JoostHopman,MD, PhD, DTMH; BenedettaAllegranzi,MD, DTMH; ShaheenMehtar,MBBS, MD (Lon)

      JAMA

    • Research Letter Detection of SARS-CoV-2 in Different Types of Clinical Specimens

      WenlingWang,PhD; YanliXu,MD; RuqinGao,MD; RoujianLu,MPH; KaiHan,BS; GuizhenWu,MD; WenjieTan,MD, PhD

      JAMA

    • Research Letter Ethics Committee Reviews of Research Applications in China for COVID-19

      HuiZhang,MBBS; FengminShao,MD, PhD; JianqinGu,MD, PhD; LiLi,MBBS; YumingWang,MD, PhD

      JAMA

    • Original Investigation Public Health Interventions and Epidemiology of the COVID-19 Outbreak in Wuhan, China

      AnPan,PhD; LiLiu,MD, PhD; ChaolongWang,PhD; HuanGuo,MD, PhD; XingjieHao,PhD; QiWang,MD, PhD; JiaoHuang,PhD; NaHe,PhD; HongjieYu,PhD; XihongLin,PhD; ShengWei,MD, PhD; TangchunWu,MD, PhD

      JAMA

    • JAMA Insights Determining How Public Health Measures Might Be Slowing COVID-19 Using the Reproduction Number (Rt)

      Thomas V.Inglesby,MD

      JAMA

    • The JAMA Forum Prescribing Paid Sick Leave—An Important Tool for Primary Care During the Pandemic

      Benjamin D.Sommers,MD, PhD; Brett E.Coburn,JD

      JAMA

    • Research Letter Time Course of a Second Outbreak of COVID-19 in Beijing, China, June-July 2020

      ZunyouWu,MD, PhD; QuanyiWang,MD; JingZhao,MS; PengYang,MD; Jennifer M.McGoogan,PhD; ZijianFeng,MD, MS; ChunHuang,MD

      JAMA

    • In the News Coronavirus Outbreak—an Evolving Global Health Emergency

      JoanStephenson,PhD

      JAMA Health Forum

    Audio (32:02)

    COVID-19 Update With NIAID's Anthony Fauci, MD; March 6, 2020

    1x

    0:00 / 0:00

    Subscribe to Podcast

    Audio Clinical Review (33:17)

    Update on Coronavirus: March 6, 2020, by NIAID’s Anthony Fauci, MD

    1x

    0:00 / 0:00

    Subscribe to Podcast

    The Chinese Center for Disease Control and Prevention recently published the largest case series to date of coronavirus disease 2019 (COVID-19) in mainland China (72 314 cases, updated through February 11, 2020).1 This Viewpoint summarizes key findings from this report and discusses emerging understanding of and lessons from the COVID-19 epidemic.

    Epidemiologic Characteristics of the COVID-19 Outbreak

    Among a total of 72 314 case records (Box), 44 672 were classified as confirmed cases of COVID-19 (62%; diagnosis based on positive viral nucleic acid test result on throat swab samples), 16 186 as suspected cases (22%; diagnosis based on symptoms and exposures only, no test was performed because testing capacity is insufficient to meet current needs), 10 567 as clinically diagnosed cases (15%; this designation is being used in Hubei Province only; in these cases, no test was performed but diagnosis was made based on symptoms, exposures, and presence of lung imaging features consistent with coronavirus pneumonia), and 889 as asymptomatic cases (1%; diagnosis by positive viral nucleic acid test result but lacking typical symptoms including fever, dry cough, and fatigue).1

    Box.

    Key Findings From the Chinese Center for Disease Control and Prevention Report

    • 72 314 Cases (as of February 11, 2020)

      • Confirmed cases: 44 672 (62%)

      • Suspected cases: 16 186 (22%)

      • Diagnosed cases: 10 567 (15%)

      • Asymptomatic cases: 889 (1%)

    • Age distribution (N = 44 672)

      • ≥80 years: 3% (1408 cases)

      • 30-79 years: 87% (38 680 cases)

      • 20-29 years: 8% (3619 cases)

      • 10-19 years: 1% (549 cases)

      • <10 years: 1% (416 cases)

    • Spectrum of disease (N = 44 415)

      • Mild: 81% (36 160 cases)

      • Severe: 14% (6168 cases)

      • Critical: 5% (2087 cases)

    • Case-fatality rate

      • 2.3% (1023 of 44 672 confirmed cases)

      • 14.8% in patients aged ≥80 years (208 of 1408)

      • 8.0% in patients aged 70-79 years (312 of 3918)

      • 49.0% in critical cases (1023 of 2087)

    • Health care personnel infected

      • 3.8% (1716 of 44 672)

      • 63% in Wuhan (1080 of 1716)

      • 14.8% cases classified as severe or critical (247 of 1668)

      • 5 deaths

    Most case patients were 30 to 79 years of age (87%), 1% were aged 9 years or younger, 1% were aged 10 to 19 years, and 3% were age 80 years or older. Most cases were diagnosed in Hubei Province (75%) and most reported Wuhan-related exposures (86%; ie, Wuhan resident or visitor or close contact with Wuhan resident or visitor). Most cases were classified as mild (81%; ie, nonpneumonia and mild pneumonia). However, 14% were severe (ie, dyspnea, respiratory frequency ≥30/min, blood oxygen saturation ≤93%, partial pressure of arterial oxygen to fraction of inspired oxygen ratio <300, and/or lung infiltrates >50% within 24 to 48 hours), and 5% were critical (ie, respiratory failure, septic shock, and/or multiple organ dysfunction or failure) (Box).1

    The overall case-fatality rate (CFR) was 2.3% (1023 deaths among 44 672 confirmed cases). No deaths occurred in the group aged 9 years and younger, but cases in those aged 70 to 79 years had an 8.0% CFR and cases in those aged 80 years and older had a 14.8% CFR. No deaths were reported among mild and severe cases. The CFR was 49.0% among critical cases. CFR was elevated among those with preexisting comorbid conditions—10.5% for cardiovascular disease, 7.3% for diabetes, 6.3% for chronic respiratory disease, 6.0% for hypertension, and 5.6% for cancer. Among the 44 672 cases, a total of 1716 were health workers (3.8%), 1080 of whom were in Wuhan (63%). Overall, 14.8% of confirmed cases among health workers were classified as severe or critical and 5 deaths were observed.1

    COVID-19 rapidly spread from a single city to the entire country in just 30 days. The sheer speed of both the geographical expansion and the sudden increase in numbers of cases surprised and quickly overwhelmed health and public health services in China, particularly in Wuhan City and Hubei Province. Epidemic curves reflect what may be a mixed outbreak pattern, with early cases suggestive of a continuous common source, potentially zoonotic spillover at Huanan Seafood Wholesale Market, and later cases suggestive of a propagated source as the virus began to be transmitted from person to person (Figure 1).1

    Figure 1. Epidemic Curve of the Confirmed Cases of Coronavirus Disease 2019 (COVID-19)

    View LargeDownload

    Daily numbers of confirmed cases are plotted by date of onset of symptoms (blue) and by date of diagnosis (orange). Because, on retrospective investigation, so few cases experienced illness in December, these cases are shown in the inset. The difference between the cases by date of symptom onset curve (blue) and the cases by date of diagnosis curve (orange) illustrates lag time between the start of illness and diagnosis of COVID-19 by viral nucleic acid testing. The graph's x-axis (dates from December 8, 2019, to February 11, 2020) is also used as a timeline of major milestones in the epidemic response. The first few cases of pneumonia of unknown etiology are shown in blue boxes on December 26 (n = 4) and 28-29 (n = 3). Most other cases that experienced onset of symptoms in December were only discovered when retrospectively investigated. Major epidemic response actions taken by the Chinese government are shown in brown boxes. The normally scheduled Lunar New Year national holiday is shown in light yellow, whereas the extended holiday during which attendance at school and work was prohibited (except for critical personnel such as health workers and police) is shown in dark yellow. This figure was adapted with permission.1 CDC indicates Chinese Center for Disease Control and Prevention; HICWM, Hubei Integrated Chinese and Western Medicine; 2019-nCoV, 2019 novel coronavirus; WHO, World Health Organization.

    Comparison of COVID-19 With SARS and MERS

    The current COVID-19 outbreak is both similar and different to the prior severe acute respiratory syndrome (SARS; 2002-2003) and Middle East respiratory syndrome (MERS; 2012-ongoing) outbreaks. SARS was initiated by zoonotic transmission of a novel coronavirus (likely from bats via palm civets) in markets in Guangdong Province, China. MERS was also traced to zoonotic transmission of a novel coronavirus (likely from bats via dromedary camels) in Saudi Arabia. All 3 viral infections commonly present with fever and cough, which frequently lead to lower respiratory tract disease with poor clinical outcomes associated with older age and underlying health conditions. Confirmation of infection requires nucleic acid testing of respiratory tract samples (eg, throat swabs), but clinical diagnosis may be made based on symptoms, exposures, and chest imaging. Supportive care for patients is typically the standard protocol because no specific effective antiviral therapies have been identified.

    The World Health Organization (WHO) declared the SARS outbreak contained on July 5, 2003. A total of 8096 SARS cases and 774 deaths across 29 countries were reported for an overall CFR of 9.6%. MERS is still not contained and is thus far responsible for 2494 confirmed cases and 858 deaths across 27 countries for a CFR of 34.4%. Despite much higher CFRs for SARS and MERS, COVID-19 has led to more total deaths due to the large number of cases. As of the end of February 18, 2020, China has reported 72 528 confirmed cases (98.9% of the global total) and 1870 deaths (99.8% of the global total). This translates to a current crude CFR of 2.6%. However, the total number of COVID-19 cases is likely higher due to inherent difficulties in identifying and counting mild and asymptomatic cases. Furthermore, the still-insufficient testing capacity for COVID-19 in China means that many suspected and clinically diagnosed cases are not yet counted in the denominator.2 This uncertainty in the CFR may be reflected by the important difference between the CFR in Hubei (2.9%) compared with outside Hubei (0.4%).1,2 Nevertheless, all CFRs still need to be interpreted with caution and more research is required.

    Most secondary transmission of SARS and MERS occurred in the hospital setting. Transmission of COVID-19 is occurring in this context as well—3019 cases have been observed among health workers as of February 11, 2020 (of whom there have been 1716 confirmed cases and 5 deaths).1 However, this is not a major means of COVID-19 spread. Rather, it appears that considerable transmission is occurring among close contacts. To date, 20 provinces outside of Hubei have reported 1183 case clusters, 88% of which contained 2 to 4 confirmed cases. Of note, 64% of clusters documented thus far have been within familial households (Chinese Center for Disease Control and Prevention presentation made to the WHO Assessment Team on February 16, 2020). Thus, although COVID-19 seems to be more transmissible than SARS and MERS, and many estimates of the COVID-19 reproductive number (R0) have already been published, it is still too soon to develop an accurate R0 estimate or to assess the dynamics of transmission. More research is needed in this area as well.

    Response to the COVID-19 Epidemic

    Since 2003, the Chinese government has improved its epidemic response capacity. Some of these efforts are evident in the response to COVID-19 (Figure 2). For example, in the 2002-2003 SARS outbreak, 300 cases and 5 deaths already had occurred by the time China reported the outbreak to the WHO, whereas in the COVID-19 outbreak, only 27 cases and zero deaths had occurred when the WHO was notified (January 3, 2020) (Figure 2). From the time of WHO notification, 2 months elapsed before SARS-CoV was identified compared with only 1 week from the time of WHO notification until 2019-nCoV was identified.

    Figure 2. Timeline Comparing the Severe Acute Respiratory Syndrome (SARS) and Coronavirus Disease 2019 (COVID-19) Outbreaks

    View LargeDownload

    The timeline of events for the SARS outbreak (left) from first case to final worldwide containment. The timeline of events for the COVID-19 outbreak (right) from the onset of symptoms for the first case on December 8, 2019, to status on February 20, 2020. Over the course of the first 2 months, more than 70 000 cases have been confirmed and many more are suspected. WHO indicates World Health Organization.

    aIdentified later retrospectively.

    The timing of the COVID-19 outbreak, prior to China’s annual Lunar New Year holiday, was an important factor as China considered how to respond to the outbreak. Culturally, this is the largest and most important holiday of the year. It is the expectation that people return to their family homes, which is the cause for the several billion person-trips made by residents and visitors during this time, mostly on crowded planes, trains, and buses. Knowing this meant each infected person could have numerous close contacts over a protracted time and across long distances, the government needed to quickly act. However, it was not only the speed of the government’s response, but also the magnitude of that response that were influenced by the impending holiday travel time. Knowing that specific treatment and prevention options, such as targeted antiviral drugs and vaccines, were not yet available for COVID-19, China focused on traditional public health outbreak response tactics—isolation, quarantine, social distancing, and community containment.3-5

    Identified case patients with COVID-19 were immediately isolated in designated wards in existing hospitals, and 2 new hospitals were rapidly built to isolate and care for the increasing numbers of cases in Wuhan and Hubei. People who had been in contact with COVID-19 cases were asked to quarantine themselves at home or were taken to special quarantine facilities, where they could be monitored for onset of symptoms. Enormous numbers of large gatherings were canceled, including all Lunar New Year celebrations, and traffic in Wuhan and in cities across Hubei was restricted and closely monitored. Virtually all transportation was subsequently restricted at a national level. All of these measures were instituted to achieve social distancing. In addition, an estimated 40 million to 60 million residents of Wuhan and 15 other surrounding cities within Hubei Province were subjected to community containment measures. Although these types of traditional outbreak response actions have been successfully used in the past, they have never been executed on such a large scale.

    There have been some questions about whether these actions are reasonable and proportional responses to the outbreak. Some have argued that a number of these approaches may infringe on the civil liberties of citizens, and some of these measures have been referred to as “draconian.” However, it is not only individual rights that must be considered. The rights of those who are not infected, but at risk of infection, must be considered as well. Whether these approaches have been effective (eg, in terms of reduced infections and deaths averted), and whether these potential benefits have outweighed the costs (eg, economic losses), will be debated for years.4,5

    Next Steps

    Importantly, another major goal of China’s current outbreak response activities is to help “buy time” for science to catch up before COVID-19 becomes too widespread. China must now focus on adjusting tactics and strategies as new evidence becomes available.3,6 Much remains to be done and many questions remain unanswered. China is very grateful for the help it is receiving from the international scientific, health, and public health communities. The global society is more interconnected than ever, and emerging pathogens do not respect geopolitical boundaries. Proactive investment in public health infrastructure and capacity is crucial to effectively respond to epidemics like COVID-19, and it is critical to continue to improve international surveillance, cooperation, coordination, and communication about this major outbreak and to be even better prepared to respond to future new public health threats.

    Back to top

    Article Information

    Corresponding Author: Zunyou Wu, MD, PhD, Chinese Center for Disease Control and Prevention, 155 Changbai Rd, Beijing 102206, China (wuzy@263.net).

    Published Online: February 24, 2020. doi:10.1001/jama.2020.2648

    Conflict of Interest Disclosures: None reported.

    Funding/Support: This work was supported by the National Health Commission of the People’s Republic of China (2018ZX10721102).

    Role of the Funder/Sponsor: The funder had no role in the preparation, review, or approval of the manuscript, or the decision to submit the manuscript for publication.

    Disclaimer: The opinions expressed herein reflect the collective views of the coauthors and do not necessarily represent the official position of the Chinese Center for Disease Control and Prevention.

    Additional Contributions: We thank China CDC Weekly for its permission to re-create the epidemic curve with modifications.

    References

    1.

    Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. Vital surveillances: the epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19)—China, 2020. China CDC Weekly. Accessed February 20, 2020. http://weekly.chinacdc.cn/en/article/id/e53946e2-c6c4-41e9-9a9b-fea8db1a8f51

    2.

    Battegay M, Kuehl R, Tschudin-Sutter S, Hirsch HH, Widmer AF, Neher RA. 2019-Novel coronavirus (2019-nCoV): estimating the case fatality rate: a word of caution. Swiss Med Wkly. 2020;150:w20203. doi:10.4414/smw.2020.20203PubMedGoogle Scholar

    3.

    McCloskey B, Heymann DL. SARS to novel coronavirus: old lessons and new lessons. Epidemiol Infect. 2020;148:e22. doi:10.1017/S0950268820000254PubMedGoogle Scholar

    4.

    Du Z, Wang L, Cauchemez S, et al. Risk for transportation of 2019 novel coronavirus disease from Wuhan to other cities in China. Emerg Infect Dis. 2020;26(5). doi:10.3201/eid2605.200146Google Scholar

    5.

    Wilder-Smith A, Freedman DO. Isolation, quarantine, social distancing and community containment: pivotal role for old-style public health measures in the novel coronavirus (2019-nCoV) outbreak. J Travel Med. 2020;taaa020. doi:10.1093/jtm/taaa020PubMedGoogle Scholar

    6.

    Cowling BJ, Leung GM. Epidemiological research priorities for public health control of the ongoing global novel coronavirus (2019-nCoV) outbreak. Euro Surveill. 2020;25(6). doi:10.2807/1560-7917.ES.2020.25.6.2000110PubMedGoogle Scholar

    Comment

    10 Comments for this article

    EXPAND ALL

    February 25, 2020

    Smoking History Linked to Mortality?

    Thomas Ferber, Dr. | Oncoletter.ch

    In all the epidemiological studies about the novel coronavirus outbreak there is no differentiation between smokers and non-smokers. Does smoking and preexisting lung disease influence morbidity and mortality?

    CONFLICT OF INTEREST: None Reported

    February 25, 2020

    Date of Onset of Symptoms in the First Patient And Supposed Source of Infection

    Giuliano Ramadori, Professor of Medicine | University Clinic Göttingen Germany

    I am grateful for the enormous amount of work done by the authors in reporting as precisely as possible the numbers and characteristics of patients demonstrated (or supposed to have been) infected by a variant of the coronavirus.

    In the report, however, I do not find a demonstration concerning the hypothesized "zoonotic spillover" as the cause of human infection. In public imagination this assumption turns the viral infection into a much stronger threat than it is.

    According to Chaolin Huang et al.(1), "the symptom onset date of the first patient identified was Dec. 1,2019."
    Therefore this date

    should be added to the very important and comprehensive epidemic curve (Figure 1) and to the timeline comparing the SARS and the COVID-19 outbreaks (Figure 2) in this report.

    REFERENCE

    1. Chaolin Huang et al.Clinical features of patients infected with 2019 novel coronavirus in Wuhan,China. The Lancet, January 24, https://doi.org/10.1016/50140-6736(20)30183-5

    CONFLICT OF INTEREST: None Reported

    READ MORE

    February 25, 2020

    Data Missing on Sex and Professions

    Hedley Quintana, MD, MSc, PhD | Gorgas Memorial Institute for Health Studies

    This article lacks data on sex and profession! Are they considered relevant regarding COVID-19 infectivity and mortality?

    CONFLICT OF INTEREST: None Reported

    February 26, 2020

    Age as a Risk Factor

    Toufique Hussain, MPH | Sindh Institute of Ophthalmology and Visual Sciences, Hyderabad Pakistan

    The authors have complicated interpretation of their data in the age group 30 to 79 years. It is a wide span that obscures different populations, and the authors should report more age groups (eg 30-45, 46-65, 66-79) to understand if any of these more precisely defined age groups is at greater risk.

    CONFLICT OF INTEREST: None Reported

    February 26, 2020

    Outbreak

    Irfan Malik, FCPS Pulmonology | Post Graduate Medical Institute, Lahore General Hospital, Lahore Pakistan

    Very important lessons and experiences shared in this short viewpoint report regarding COVID-19, a recent horrible outbreak of viral infection in China. Detailed data is shared related to this disease like age, sex and epidemiological distributions which are very informative for understanding the severity of this viral infection. Though many people suffer from this infection, mortality is not high. This report also shows that a large number of healthcare workers (HCWs) were affected in this viral outbreak, which is an eye opener for HCWs to be vigilant in treating people and to follow infection prevention and control standard precautions.
    />
    This report also highlights the active precautionary measures which took place in response to this contagious disease in China. It would be challenging to enact the same measures in developing countries like Pakistan. China is a developed country and took all these precautionary measures in a very short period. In contrast, resources in developing countries like Pakistan are limited, and it would be difficult to take comparable precautionary measures against contagious infectious illnesses in the same period of time. China as a nation is so united it’s a lesson for other countries to face critical public health situations with similar unity.

    CONFLICT OF INTEREST: None Reported

    READ MORE

    February 28, 2020

    Follow-up Data Missing on Discharged Patients

    Zhiyan Liu, PhD | Peking University First Hospital

    As of February 27, 36117 cases had been cured and discharged in China. The follow-up data of cured patients were not reported and analyzed, including the positive rate of nucleic acid test and clinical symptoms within 14 days.

    CONFLICT OF INTEREST: None Reported

    February 29, 2020

    False Diagnoses and Reinfection

    Michael McAleer, PhD (Econometrics) | Asia university

    This highly informative viewpoint cannot cover all issues, so two queries are as follows:

    1. What is the possibility of having false positives or false negatives arising from checks for COVID-19?

    2. Is there any possibility of reinfection after purported recovery and, if so, how soon can this occur?

    CONFLICT OF INTEREST: None Reported

    March 1, 2020

    Occurrence of Infections and Mild and Subclinical disease

    Victor Cardenas, MD, MPH, PhD | University of Arkansas for Medical Sciences Fay W. Boozman College of Public Health

    I have read with great interest the report on behalf of the Chinese CDC team, and I am puzzled by the low frequency of reports of cases among children. I believe age-specific rates would have been more informative. A burning question before us is whether or not there are cases of mild acute respiratory infections (ARI) in children, possibly not severe enough to merit a visit to an emergency room? One quick look at the reported figures of office visits for ARI would be valuable, to see whether the figures have remained stable in the affected provinces. In your report I could not find out if there has been a systematic effort to investigate the occurrence of any respiratory symptoms including mild disease among contacts of cases. Since it is unlikely that children are not susceptible to the SARS-2 virus, and in some instances recent cases in the US seemed to have no obvious source case among contacts, the possibility of some spread through asymptomatic carriers or persons with mild disease could play role in the transmission. More population-based epidemiological and laboratory-based research possibly in households is needed to answer the question of why the risk among children seems small.

    CONFLICT OF INTEREST: None Reported

    READ MORE

    March 7, 2020

    Where are Clinically Diagnosed Cases Now?

    Padmanabhan VT, Master Community Health | Freelancer

    Regarding the clinically diagnosed cases in Hubei province, the authors do not explain as to why “no test was performed but diagnosis was made based on symptoms, exposures, and presence of lung imaging features consistent with coronavirus pneumonia.” In fact the clinically diagnosed group was mentioned only once in the report from the Health Commission of Hubei province on 11 Feb 2020. NHC or CDC did not mention this group in any report. According to the CDC report, on March 07, 2020 there were 80,651 confirmed cases and 502 suspected cases.

    The clinically

    diagnosed group disappeared because they were added to the confirmed list during 12-15 Feb 2020.

    The WHO’s situation reports for 12 to 16 Feb 2020 did not include these cases. The situation report for 16 Feb had 51,174 laboratory confirmed cases in China and on 17 Feb 2020 there were 70,635 confirmed cases in China, which included the clinical cases also. The WHO now reports cases in China as confirmed and cases from rest of the world as laboratory-confirmed.

    The WHO’s definitions of confirmed and probable cases of COVID-19 are reproduced below:

    Confirmed case: A person with laboratory confirmation of COVID-19 infection, irrespective of clinical signs and symptoms.

    Probable case: A suspect case for whom testing for COVID-19 is inconclusive. • Inconclusive being the result of the test reported by the laboratory.

    Detailed report at:

    https://www.researchgate.net/publication/339746617_final_2A1

    CONFLICT OF INTEREST: None Reported

    READ MORE

    April 8, 2020

    Paciente Asintomático

    David Ezequiel Garcia, Licenciado en enfermería | Hospital general de occidente.

    Los paciente asintomaticos mencionados en la estadistica fueron positivos a RT-PCR?

    Were the asymptomatic patients mentioned in the reporting of patients positive for RT-PCR?

    CONFLICT OF INTEREST: None Reported

    See More About

    Coronavirus (COVID-19) Global Health Infectious Diseases Public Health

    Download PDF

    Cite This

    Citation

    Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239–1242. doi:10.1001/jama.2020.2648

    Manage citations:

    Ris (Zotero) EndNote BibTex Medlars ProCite RefWorks Reference Manager Mendeley

    © 2024

    Comment

    Artificial Intelligence ResourceCenter

    Others Also Liked

    X

    .

    ×

    Access your subscriptions

    Add or change institution

    Free access to newly published articles

    To register for email alerts, access free PDF, and more

    Purchase access

    Get full journal access for 1 year

    Get unlimited access and a printable PDF ($40.00)—
    Sign in or create a free account

    Rent this article from DeepDyve

    Access your subscriptions

    Add or change institution

    Free access to newly published articles

    To register for email alerts, access free PDF, and more

    Purchase access

    Get full journal access for 1 year

    Get unlimited access and a printable PDF ($40.00)—
    Sign in or create a free account

    Rent this article from DeepDyve

    Sign in to access free PDF

    Add or change institution

    Free access to newly published articles

    To register for email alerts, access free PDF, and more

    Save your search

    Free access to newly published articles

    To register for email alerts, access free PDF, and more

    Purchase access

    Customize your interests

    Free access to newly published articles

    To register for email alerts, access free PDF, and more

    Create a personal account or sign in to:

    • Register for email alerts with links to free full-text articles
    • Access PDFs of free articles
    • Manage your interests
    • Save searches and receive search alerts

      Privacy Policy

      Make a comment

      Free access to newly published articles

      To register for email alerts, access free PDF, and more

      Create a personal account or sign in to:

      • Register for email alerts with links to free full-text articles
      • Access PDFs of free articles
      • Manage your interests
      • Save searches and receive search alerts

        Privacy Policy

        The Coronavirus Disease 2019 (COVID-19) Outbreak in China—Summary of a China CDC Report (2024)

        References

        Top Articles
        Latest Posts
        Article information

        Author: Pres. Carey Rath

        Last Updated:

        Views: 5841

        Rating: 4 / 5 (61 voted)

        Reviews: 84% of readers found this page helpful

        Author information

        Name: Pres. Carey Rath

        Birthday: 1997-03-06

        Address: 14955 Ledner Trail, East Rodrickfort, NE 85127-8369

        Phone: +18682428114917

        Job: National Technology Representative

        Hobby: Sand art, Drama, Web surfing, Cycling, Brazilian jiu-jitsu, Leather crafting, Creative writing

        Introduction: My name is Pres. Carey Rath, I am a faithful, funny, vast, joyous, lively, brave, glamorous person who loves writing and wants to share my knowledge and understanding with you.